A phase I, first‐in‐human study investigating the safety, tolerability, and pharmacokinetics of the maturation inhibitor GSK3739937

We report the safety and pharmacokinetic properties of the HIV‐1 maturation inhibitor GSK3739937 (GSK'937) in healthy participants. This was a phase I, first‐in‐human, double‐blind, randomized, placebo‐controlled, single‐ (part 1) and multiple‐ (part 2) dose escalation study with an additional...

Descripción completa

Detalles Bibliográficos
Autores principales: Benn, Paul D., Zhang, Ying, Kahl, Lesley, Greene, Thomas J., Bainbridge, Veronica, Fishman, Cindy, Wen, Bo, Gartland, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10238757/
https://www.ncbi.nlm.nih.gov/pubmed/37269076
http://dx.doi.org/10.1002/prp2.1093

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10238757/
https://www.ncbi.nlm.nih.gov/pubmed/37269076
http://dx.doi.org/10.1002/prp2.1093

Ejemplares similares